A clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells, its preparation method and application

By using a cryopreservation solution with simplified components, the problems of complex cryopreservation solution composition and the need for thawing and testing are solved, achieving high safety and high efficiency in cryopreservation, and ensuring direct detection of cell viability and biomarkers.

CN118303389BActive Publication Date: 2026-11-17YANTAI ZHENGHAI BIO TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410411622.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-08
Publication Date
2026-11-17
Estimated Expiration
2044-04-08

AI Technical Summary

Technical Problem

In existing technologies, the cryopreservation solution for human umbilical cord mesenchymal stem cells has a complex composition, posing safety risks. Furthermore, the cells require thawing after cryopreservation before biomarkers can be detected, which affects detection efficiency.

Method used

The cryopreservation solution is composed of human serum albumin, trehalose, DMSO, polyvinylpyrrolidone, ectoine, and sericin, simplifying the composition, ensuring safety, and allowing for the detection of biomarkers without thawing after cryopreservation.

Benefits of technology

The cryopreservation effect is stable, with a cell viability of over 90%. The cryopreservation solution has a clear composition, high safety, simplified operation process, reduced risk of contamination, and enables direct detection of biomarkers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004779366120000061
    Figure BDA0004779366120000061
  • Figure BDA0004779366120000071
    Figure BDA0004779366120000071
  • Figure BDA0004779366120000081
    Figure BDA0004779366120000081
Patent Text Reader

Abstract

This invention relates to the field of stem cell cryopreservation solutions, specifically to a clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution, its preparation method, and its application. By weight percentage, the cryopreservation solution comprises 6%-8% human serum albumin, 2%-4% trehalose, 4%-6% dimethyl sulfoxide, 0.5%-2% polyvinylpyrrolidone, 0.2%-1% ectoine, and 0.5%-2% sericin; the balance is a solvent, specifically a compound electrolyte injection solution. The cryopreservation solution of this invention exhibits good cryopreservation effects on human umbilical cord mesenchymal stem cells, maintaining a cell viability of over 90% during a 6-month storage period, with stable cryopreservation performance. The cryopreservation solution has a simple composition, higher safety, and allows for biomarker detection of cryopreserved human umbilical cord mesenchymal stem cells without the need for thawing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells, its preparation method, and its application, belonging to the field of stem cell cryopreservation solution technology. Background Technology

[0002] Human umbilical cord mesenchymal stem cells (hUCMSCs) are pluripotent stem cells with a certain degree of self-renewal capacity, induced differentiation potential, unique immunomodulatory functions, and tissue regeneration capabilities. Due to their advantages such as convenient sourcing, simple and rapid in vitro expansion, and low immunogenicity, they are widely used to treat various clinical diseases. Currently, clinical research on hUCMSCs mainly focuses on the treatment of cardiovascular and cerebrovascular diseases, bone and joint diseases, diabetes, neurodegenerative diseases, graft-versus-host disease (GvHD), and functional impairment or failure of various tissues and organs.

[0003] In the preparation and clinical application of stem cells, the main preservation methods are cryopreservation and refrigeration. Refrigeration has disadvantages such as short preservation time and difficulty in long-distance transportation, while cryopreservation can avoid these disadvantages. However, conventional cryopreservation solutions used in cryopreservation contain unknown components such as animal serum. These components may cause cross-infection of viruses or pathogens when stem cells are used clinically. Therefore, it is necessary to develop a cryopreservation solution for human umbilical cord mesenchymal stem cells that is free of animal serum and culture medium and has clearly defined components. This stem cell cryopreservation solution can maintain high cell viability after cryopreservation and thawing, while meeting the requirements for long-distance transportation, and allows the cells to be directly used clinically after thawing.

[0004] Currently, in order to provide a favorable environment for cell survival, protect cells from damage, and maintain their long-term viability, cryopreservation solutions often require very complex components. For example, Chinese patent application CN109329271A discloses a clinical mesenchymal stem cell cryopreservation solution and its preparation method. This cryopreservation solution comprises the following components by weight percentage: 1-5% autologous plasma lysate mixture, 1-2% human serum albumin, 0-1% vitamin C injection, 5-10% glucose injection, 20-30% electrolyte solution, 20-30% glucose saline injection, 20-30% compound amino acid injection, 2-5% dimethyl sulfoxide, and 2.5-5% trehalose. This formulation is very complex, involving many substances. However, for the cryopreservation of human umbilical cord mesenchymal stem cells, the simpler the composition of the cryopreservation solution, the safer its use. In addition, in conventional techniques, after cryopreservation of human umbilical cord mesenchymal stem cells, the stem cells need to be thawed and regenerated before biomarker detection can be performed. If a cryopreservation solution could be developed that allows human umbilical cord mesenchymal stem cells to be cryopreserved without thawing and regenerating, biomarker detection could be performed directly, which would facilitate subsequent detection work. Summary of the Invention

[0005] This invention addresses the shortcomings of existing technologies by providing a clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells, its preparation method, and its application. The cryopreservation solution has simple components, higher safety, and stable cryopreservation effect on human umbilical cord mesenchymal stem cells. Moreover, the cryopreserved human umbilical cord mesenchymal stem cells can be used to detect biomarkers without thawing.

[0006] The technical solution of the present invention to solve the above-mentioned technical problems is as follows: a clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution, wherein, by mass percentage, the cryopreservation solution comprises 6%-8% human serum albumin, 2%-4% trehalose, 4%-6% dimethyl sulfoxide (DMSO), 0.5%-2% polyvinylpyrrolidone (PVP), 0.2%-1% ectoine, and 0.5%-2% sericin; the balance being solvent.

[0007] Preferably, the solvent is a compound electrolyte injection solution.

[0008] Preferably, in the cryopreservation solution, the total mass percentage of dimethyl sulfoxide and polyvinylpyrrolidone is 5%-6%, and the mass ratio of dimethyl sulfoxide to polyvinylpyrrolidone is (2-6):1.

[0009] Preferably, the total mass percentage of trehalose and ectoine in the cryopreservation solution is 2.5%-4.5%.

[0010] Preferably, in the cryopreservation solution, the total mass ratio of the polyvinylpyrrolidone and the trehalose to the dimethyl sulfoxide is (0.7-1.3):1.

[0011] Preferably, the cryopreservation solution comprises, by weight percentage, 6% human serum albumin, 4% trehalose, 4% dimethyl sulfoxide, 1% polyvinylpyrrolidone, 0.5% ectoine, and 1% sericin; the remainder is a compound electrolyte injection solution.

[0012] This invention also discloses a method for preparing a clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution. The preparation method is as follows: human serum albumin, trehalose, dimethyl sulfoxide, polyvinylpyrrolidone, ectoin, sericin and solvent are mixed evenly in the prescribed amounts, and then sterilized to obtain the cryopreservation solution.

[0013] Further, trehalose, polyvinylpyrrolidone, and sericin are dissolved in a compound electrolyte injection solution with a total solvent mass of 50%-60%, filtered through a 0.2-0.25 μm filter membrane, and then dimethyl sulfoxide, the remaining solvent mass of the compound electrolyte injection solution, and ecoxib are added sequentially. Human serum albumin is slowly added while shaking, and after mixing evenly, the mixture is filtered to obtain the cryopreservation solution.

[0014] The present invention also discloses the application of a clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells, wherein the cryopreservation solution is used for the cryopreservation of human umbilical cord mesenchymal stem cells.

[0015] Furthermore, human umbilical cord mesenchymal stem cells were resuspended in the cryopreservation solution at 20-25°C, and the density of the human umbilical cord mesenchymal stem cells was (3×10⁻⁶). 6 )~(4×10 7 () per ml; then use a programmed cooling system to freeze the cells, and after freezing, transfer them to an -80℃ ultra-low temperature freezer or liquid nitrogen for storage.

[0016] The beneficial effects of this invention are:

[0017] The cryopreservation solution described in this invention has a good cryopreservation effect on human umbilical cord mesenchymal stem cells, with a cell viability of over 90% during a 6-month storage period, and the cryopreservation effect is stable. The cryopreservation solution has a simple composition, higher safety, and the cryopreserved human umbilical cord mesenchymal stem cells can be used for biomarker detection without thawing.

[0018] The cryopreservation solution of this invention uses clearly defined raw materials, contains no animal-derived components, and has high safety for clinical application. DMSO is a permeable cryoprotectant that easily penetrates cells, lowering the freezing point during cell cryopreservation and reducing the chance of ice crystal formation within stem cells, thereby minimizing ice crystal damage. Human serum albumin is a non-permeable cryoprotectant with strong protective effects on cells, prolonging cell survival time and maintaining relatively stable cell osmotic pressure, ensuring the safety of human umbilical cord mesenchymal stem cells during cryopreservation. Trehalose is a non-permeable cryoprotectant that interacts with cell membranes, stabilizing the structure of cell membrane proteins during cryopreservation and thawing. Trehalose also forms a glassy matrix, reducing damage to cells caused by ice crystals forming outside the stem cells and improving the viability of the stem cell cryopreservation solution during cell freeze-thaw cycles. The compound electrolyte injection solution can protect cells during cryopreservation at temperatures as low as -130°C and can be directly used as an electrolyte injection solution in humans after thawing, without additional processing steps, thus reducing operational procedures and the probability of contamination.

[0019] In the cryopreservation solution described in this invention, polyvinylpyrrolidone has excellent biocompatibility, providing excellent permeability protection for stem cells and preventing the formation of ice crystals between cells. In addition, the ratio of dimethyl sulfoxide to polyvinylpyrrolidone specified in this invention provides excellent suspension of stem cells, avoiding compression between stem cells during cryopreservation and making it more conducive to the cryopreservation of human umbilical cord mesenchymal stem cells.

[0020] In the cryopreservation solution of this invention, polyvinylpyrrolidone and trehalose can reduce the chance of ice crystal formation between stem cells during cryopreservation, while dimethyl sulfoxide can reduce the chance of ice crystal formation inside stem cells. The amounts of polyvinylpyrrolidone, trehalose, and dimethyl sulfoxide specified in this invention, as well as the mass ratio of the total mass of polyvinylpyrrolidone and trehalose to the mass of dimethyl sulfoxide, can effectively balance the cryopreservation state between the inside and outside of stem cells, improving the stability of human umbilical cord mesenchymal stem cell cryopreservation. At the same time, in combination with ingredients such as ecoxib and sericin in the formula, while stabilizing the cryopreservation effect of human umbilical cord mesenchymal stem cells, it also allows for the detection of biomarkers in cryopreserved human umbilical cord mesenchymal stem cells without thawing. Detailed Implementation

[0021] The specific embodiments of the present invention will be described in detail below. The present invention can be implemented in many other ways different from those described herein, and those skilled in the art can make similar modifications without departing from the spirit of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed.

[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used is for describing particular embodiments only and is not intended to limit the invention.

[0023] A clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells, comprising, by weight percentage, 6%-8% human serum albumin, 2%-4% trehalose, 4%-6% dimethyl sulfoxide, 0.5%-2% polyvinylpyrrolidone, 0.2%-1% ectoine, and 0.5%-2% sericin; the remainder being solvent.

[0024] Specifically, the solvent is a compound electrolyte injection solution.

[0025] Specifically, in the cryopreservation solution, the total mass percentage of dimethyl sulfoxide and polyvinylpyrrolidone is 5%-6%, and the mass ratio of dimethyl sulfoxide to polyvinylpyrrolidone is (2-6):1.

[0026] Specifically, the total mass percentage of trehalose and ectoine in the cryopreservation solution is 2.5%-4.5%.

[0027] Specifically, in the cryopreservation solution, the total mass ratio of the polyvinylpyrrolidone and the trehalose to the dimethyl sulfoxide is (0.7-1.3):1.

[0028] Specifically, by mass percentage, the cryopreservation solution comprises 6% human serum albumin, 4% trehalose, 4% dimethyl sulfoxide, 1% polyvinylpyrrolidone, 0.5% ectoine, and 1% sericin; the remainder is compound electrolyte injection solution.

[0029] A method for preparing a clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells, wherein the preparation method comprises: mixing human serum albumin, trehalose, dimethyl sulfoxide, polyvinylpyrrolidone, ectoin, sericin and solvent in the prescribed amounts until homogeneous, and then sterilizing the mixture to obtain the cryopreservation solution.

[0030] Specifically, trehalose, polyvinylpyrrolidone, and sericin are dissolved in a compound electrolyte injection solution with a total solvent mass of 50%-60%, filtered through a 0.2-0.25 μm filter membrane, and then dimethyl sulfoxide, the remaining solvent mass of the compound electrolyte injection solution, and ecoxib are added sequentially. Human serum albumin is slowly added while shaking, and after mixing evenly, the mixture is filtered to obtain the cryopreservation solution.

[0031] Application of a clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells, wherein the cryopreservation solution is used for the cryopreservation of human umbilical cord mesenchymal stem cells.

[0032] Specifically, human umbilical cord mesenchymal stem cells were resuspended in the cryopreservation solution at 20-25°C, and the density of the human umbilical cord mesenchymal stem cells was (3×10⁻⁶). 6 )~(4×10 7() per ml; then use a programmed cooling system to freeze the cells, and after freezing, transfer them to an -80℃ ultra-low temperature freezer or liquid nitrogen for storage.

[0033] More specifically, the programmed cooling system set in the programmed cooling device is as follows:

[0034] Step 1: Set the chamber temperature to 4.0℃ and wait until the sample temperature drops to 5.0℃;

[0035] Step 2: Maintain at 4.0℃ for 10.0 min;

[0036] Step 3: Cool the sample temperature to -4.0℃ at a rate of 1.0℃ / min;

[0037] Step 4: Reduce the temperature of the programmed cooling instrument chamber to -40.0℃ at a cooling rate of 25.0℃ / min;

[0038] Step 5: Cool the chamber temperature of the programmed cooling instrument to -12.0℃ at a cooling rate of 10.0℃ / min;

[0039] Step 6: Reduce the temperature of the programmed cooling instrument chamber to -40.0℃ at a cooling rate of 1.0℃ / min;

[0040] Step 7: Reduce the temperature of the programmed cooling instrument chamber to -80.0℃ at a cooling rate of 10.0℃ / min;

[0041] Step 8: Maintain at -80.0℃ for 15.0 min;

[0042] Step 9: End.

[0043] I. Examples of Cryopreservation Solution Preparation

[0044] Example 1

[0045] Preparation of a clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells:

[0046] The cryopreservation solution comprises, by weight percentage, 6% human serum albumin, 4% trehalose, 4% dimethyl sulfoxide, 1% polyvinylpyrrolidone, 0.5% ectoine, and 1% sericin; the remainder is compound electrolyte injection solution.

[0047] Dimethyl sulfoxide (DMSO): Hunan Jiudian Hongyang Pharmaceutical Co., Ltd., pharmaceutical excipient;

[0048] Human serum albumin (HSA): Baxter AG, injection;

[0049] Trehalose: supplied by Aivit (Shanghai) Pharmaceutical Technology Co., Ltd. as a pharmaceutical excipient for injection.

[0050] Polyvinylpyrrolidone (PVP): Sigma-Aldrich PVP K 30;

[0051] Ectoin: Sigma-Aldrich E2271;

[0052] Sericin (CAS: 60650-88-6): Hubei Weideli Chemical

[0053] Compound electrolyte injection: Baxter AG, injection.

[0054] Trehalose, polyvinylpyrrolidone, and sericin were dissolved in 50% of the total solvent mass of compound electrolyte injection solution, filtered through a 0.22 μm filter membrane, and then dimethyl sulfoxide, the remaining solvent mass of compound electrolyte injection solution, and ecoxib were added sequentially. Human serum albumin was slowly added while shaking, and after mixing evenly, the mixture was filtered to obtain the cryopreservation solution.

[0055] Examples 2-9

[0056] The cryopreservation solution was prepared using the same method as in Example 1, except that the formulation composition was changed. The specific formulation composition is shown in Table 1.

[0057] Comparative Example 1

[0058] The cryopreservation solution was prepared using the same method as in Example 1, except that the amount of PVP was increased so that the mass ratio of the total mass of polyvinylpyrrolidone and trehalose to dimethyl sulfoxide was 1.5:1 (not within the range of the proportions specified in this invention). The specific formulation is shown in Table 1.

[0059] Comparative Example 2

[0060] The cryopreservation solution was prepared using the same method as in Example 1, except that the amount of PVP was reduced so that the total mass percentage of dimethyl sulfoxide and polyvinylpyrrolidone was 4.5%, and the mass ratio of dimethyl sulfoxide to polyvinylpyrrolidone was 8:1 (not within the range of the proportions defined in this invention). The specific formulation is shown in Table 1.

[0061] Comparative Example 3

[0062] The cryopreservation solution was prepared using the same method as in Example 1, except that the amount of DMSO was reduced. The specific formulation is shown in Table 1.

[0063] Comparative Example 4

[0064] The cryopreservation solution was prepared using the same method as in Example 1, except that edodein was not added. The specific formulation is shown in Table 1.

[0065] Comparative Example 5

[0066] The cryopreservation solution was prepared using the same method as in Example 1, except that no sericin was added. The specific formulation is shown in Table 1.

[0067] Table 1. Composition of cryopreservation solutions in Examples 1-9 and Comparative Examples 1-5

[0068]

[0069] II. Surface Marker Detection

[0070] The specific testing method is as follows:

[0071] (1) Cell preparation

[0072] Resuscitate human umbilical cord mesenchymal stem cells (P2 generation) at a rate of 1.5 × 10⁻⁶. 6 Cells were seeded per flask into T175 cell culture flasks and cultured at 37°C with 5% CO2 until confluence reached 80-90%, then passaged. After passage, cells were cultured for a further period until confluence reached 80-90%, at which point the cells were digested and collected.

[0073] (2) Cell cryopreservation

[0074] Resuspend the cells in cryopreservation solution to a cell concentration of 1×10⁻⁶. 7 Dispense the sample at 1 ml per vial into cryovials, transfer them to a programmed freezing apparatus, and freeze them using the pre-set program. After freezing, transfer them to liquid nitrogen for storage.

[0075] (3) Resuscitate cells for viability testing and surface marker detection.

[0076] The frozen cells were removed from the liquid nitrogen tank and transferred to a preheated water bath at 37±2℃. The frozen cells were continuously shaken to thaw them quickly, and their viability was detected using an automated fluorescent cell analyzer with AO / PI dye.

[0077] Cryopreserved stem cells were directly analyzed for surface markers CD105, CD71, and CD45 using flow cytometry without thawing.

[0078] Parallel experiments were conducted on Example 1, Comparative Examples 1-5, and the control cryopreservation solution. The specific results are shown in Table 2 below.

[0079] The specific preparation process of the control cryopreservation solution A in Table 2 is as follows:

[0080] Serum-free culture medium (GMP grade) and serum-free culture medium additive (GMP grade) for mesenchymal stem cells were mixed at a volume ratio of 100:1 to prepare a serum-free complete culture medium. DMSO was added to the serum-free culture medium, mixed well, and then set aside for use. The volume ratio of serum-free complete culture medium to DMSO was 9:1.

[0081] Table 2 Results of surface marker determination

[0082]

[0083]

[0084] As can be seen from the data in Table 2, the survival rate of stem cells cryopreserved in the cryopreservation solution described in this invention is significantly higher after thawing, and the surface markers CD71, CD105, and CD45 are stable. Furthermore, for stem cells cryopreserved in the cryopreservation solution of Example 1, after 6 months of thawing, the measured surface markers CD71, CD105, and CD45 were 97.6%, 98.4%, and 0.5%, respectively. These values ​​are very similar to the surface markers measured in Table 2 for stem cells cryopreserved in the cryopreservation solution of Example 1 without thawing after 6 months. Therefore, accurate detection of biomarkers can be achieved using the cryopreservation solution described in this invention for human umbilical cord mesenchymal stem cells without thawing.

[0085] III. Stability Testing of Human Umbilical Cord Mesenchymal Stem Cells in Cryopreservation

[0086] The specific testing method is as follows:

[0087] (1) Cell preparation

[0088] Resuscitate human umbilical cord mesenchymal stem cells at a rate of 1.5 × 10⁻⁶. 6 Cells were seeded per flask into T175 cell culture flasks and cultured at 37°C and 5% CO2 until the confluence reached 80-90%, at which point the cells were digested and collected.

[0089] (2) Cell cryopreservation

[0090] Resuspend the cells in cryopreservation solution to a cell concentration of 3 × 10⁻⁶. 6 Dispense the sample at 1 ml per vial into cryovials, transfer them to a programmed freezing apparatus, and freeze them using the pre-set program. After freezing, transfer them to an ultra-low temperature freezer at -80°C for storage.

[0091] (3) Resuscitate cells for viability testing

[0092] The frozen cells were removed from the -80℃ ultra-low temperature freezer and transferred to a preheated water bath at 37±2℃. The frozen cells were continuously shaken to thaw them quickly. The viability was detected using an automated fluorescent cell analyzer with AO / PI dye. The specific results are shown in Table 3 below.

[0093] Table 3 shows the viability of stem cells cryopreserved using the cryopreservation solutions from Examples 1-9 and Comparisons 1-5.

[0094]

[0095] As can be seen from the data in Table 3 above, the cryopreservation solutions described in this invention (Examples 1-9) all maintain high activity after cell revival and can be stably stored for up to 12 months. Because higher concentrations of added components in the cryopreservation solution increase the risk of adverse effects, the formulation of Example 1 is preferred, as it uses relatively small amounts of DMSO and HSA.

[0096] A comparison of the data from Example 1 and Comparative Examples 1-2 shows that the PVP dosage and the ratio between the PVP and other components specified in this invention are more conducive to obtaining a cryopreservation solution with excellent performance. Because polyvinylpyrrolidone (PVP) has excellent biocompatibility, it provides excellent permeability protection for stem cells, preventing the formation of ice crystals between cells. The ratio of dimethyl sulfoxide (DMSO) to PVP specified in this invention provides excellent suspension of stem cells, avoiding compression between stem cells during cryopreservation, which is more conducive to the cryopreservation of human umbilical cord mesenchymal stem cells. PVP and trehalose can reduce the chance of ice crystal formation between stem cells during cryopreservation, while DMSO can reduce the chance of ice crystal formation inside stem cells. The dosages of PVP, trehalose, and DMSO specified in this invention, as well as the ratio of the total mass of PVP and trehalose to the mass of DMSO, can effectively balance the cryopreservation state between the inside and outside of stem cells, improving the stability of the cryopreservation effect of human umbilical cord mesenchymal stem cells.

[0097] A comparison of the data from Example 1 and Comparative Examples 1-2 shows that the DMSO dosage specified in this invention is more conducive to obtaining cryopreservation solutions with excellent performance. This is because DMSO is a permeable preservative that easily penetrates cells. During cell cryopreservation, it can lower the freezing point, reducing the chance of ice crystal formation within the cells and thus minimizing ice crystal damage. However, DMSO has a certain degree of toxicity to cells; it can bind to proteins, causing protein denaturation and thus posing a hazard. Therefore, the dosage of DMSO should not be excessive.

[0098] A comparison of the data from Example 1 and Comparative Examples 4-5 shows that the addition of ectoin to the cryopreservation solution formulation is more conducive to the cryopreservation stability of stem cells. Besides its permeability protection function, ectoin also enhances the ability of stem cells to resist harsh external environments; sericin also protects the outer wall of stem cells. The combined use of ectoin and sericin in the formulation not only ensures stable cryopreservation of human umbilical cord mesenchymal stem cells but also allows for the detection of biomarkers in cryopreserved human umbilical cord mesenchymal stem cells without thawing.

[0099] IV. Determining the cryopreservation effect of cryopreservation solutions on cells of different concentrations

[0100] The number of cells per unit volume of cryopreservation solution is a key factor affecting the viability of cryopreserved cells during long-term storage. Examples 2 and 9 were selected for experiments to compare the cryopreservation effects of cryopreservation solutions on cells of different concentrations.

[0101] The determination method is as follows:

[0102] (1) Cell preparation

[0103] Resuscitate human umbilical cord mesenchymal stem cells at a rate of 1.5 × 10⁻⁶. 6 Cells were seeded per flask into T175 cell culture flasks and cultured at 37°C and 5% CO2 until the confluence reached 80-90%, at which point the cells were digested and collected.

[0104] (2) Cell cryopreservation

[0105] Resuspend the cells in cryopreservation solution to a cell concentration of 3 × 10⁻⁶. 6 cells / ml, 2×10 7 / ml and 4×10 7 / ml, dispensed into cryovials at 1ml / vial, transferred to a programmed freezing instrument and frozen using the set program, and then transferred to an ultra-low temperature freezer at -80℃ for storage.

[0106] (3) Resuscitate cells for viability testing

[0107] The frozen cells were removed from the -80℃ ultra-low temperature freezer and transferred to a preheated water bath at 37±2℃. The cells were continuously shaken to thaw them rapidly, and their viability was detected using an automated fluorescent cell analyzer with AO / PI dye. The experimental results are shown in Table 4.

[0108] Table 4. Cryopreservation effects of cryopreservation solutions on cells of different concentrations.

[0109]

[0110] As can be seen from the data in Table 4, the cryopreservation solution described in this invention has a good cryopreservation effect on cells of different concentrations, with a cell viability of over 90% during a 6-month storage period, and the cryopreservation effect is stable.

[0111] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are exhaustively listed. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0112] For those skilled in the art, various modifications and improvements can be made without departing from the concept of the present invention, and these modifications and improvements are all within the scope of protection of the present invention. The scope of protection of the present invention is defined by the appended claims.

Claims

1. A clinical-grade cryopreservation solution for human umbilical cord mesenchymal stem cells, characterized in that, The cryopreservation solution comprises, by mass percentage, 6%-8% human serum albumin, 2%-4% trehalose, 4%-6% dimethyl sulfoxide, 0.5%-2% polyvinylpyrrolidone, 0.2%-1% ectoine, and 0.5%-2% sericin; the remainder is solvent.

2. The clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to claim 1, characterized in that, The solvent is a compound electrolyte injection solution.

3. The clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to claim 1, characterized in that, In the cryopreservation solution, the total mass percentage of dimethyl sulfoxide and polyvinylpyrrolidone is 5%-7%, and the mass ratio of dimethyl sulfoxide to polyvinylpyrrolidone is (2-6):

1.

4. The clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to claim 1, characterized in that, In the cryopreservation solution, the total mass percentage of trehalose and ectoine is 2.5%-4.5%.

5. The clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to claim 1, characterized in that, In the cryopreservation solution, the total mass ratio of the polyvinylpyrrolidone and the trehalose to the dimethyl sulfoxide is (0.7-1.3):

1.

6. The clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to claim 1, characterized in that, The cryopreservation solution comprises, by weight percentage, 6% human serum albumin, 4% trehalose, 4% dimethyl sulfoxide, 1% polyvinylpyrrolidone, 0.5% ectoine, and 1% sericin; the remainder is compound electrolyte injection solution.

7. A method for preparing a clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to any one of claims 1-6, characterized in that, The preparation method is as follows: human serum albumin, trehalose, dimethyl sulfoxide, polyvinylpyrrolidone, ectoin, sericin and solvent are mixed evenly and then sterilized to obtain the cryopreservation solution.

8. The method for preparing a clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to claim 7, characterized in that, Trehalose, polyvinylpyrrolidone, and sericin were dissolved in a compound electrolyte injection solution with a total solvent mass of 50%-60%. The solution was then filtered through a 0.2-0.25 μm filter membrane. Dimethyl sulfoxide, the remaining compound electrolyte injection solution, and ectoin were added sequentially. Human serum albumin was slowly added while shaking. After mixing thoroughly, the solution was filtered to obtain the cryopreservation solution.

9. An application of a clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to any one of claims 1-6, characterized in that, The cryopreservation solution is used for the cryopreservation of human umbilical cord mesenchymal stem cells.

10. The application of the clinical-grade human umbilical cord mesenchymal stem cell cryopreservation solution according to claim 9, characterized in that, Human umbilical cord mesenchymal stem cells were resuspended in the cryopreservation solution at 20-25°C, and the density of the human umbilical cord mesenchymal stem cells was (3×10⁻⁶). 6 )~(4×10 7 () per ml; then use a programmed cooling system to freeze the cells, and after freezing, transfer them to an -80℃ ultra-low temperature freezer or liquid nitrogen for storage.

Citation Information

Patent Citations

  • Clinical mesenchymal stem cell cryopreservation solution and preparation method thereof

    CN109329271A

  • Cryopreservation liquid for long-term preservation of human umbilical cord mesenchymal stem cells

    CN112841174A

  • Human umbilical cord mesenchymal stem cell injection cryopreservation liquid and preparation method thereof

    CN112889810A